A Phase 2 interventional study of [S,S]-Reboxetine + Pregabalin and Pregabalin in Pain, sponsored by Pfizer. Terminated at 83 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-16.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing pregabalin in Pain — 4 open to participants now, 4 under way, none of them phase 3. Pregabalin · Pain.
Among the 55 studies testing pregabalin in Pain, this one is the 19th largest by enrollment, is one of 3 that started in 2006, is one of 7 in phase 2, and was the 3rd registered.
10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →4 of the 55 studies testing pregabalin in Pain are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–65
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 17 · Phase 4 14
First in 2001; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 64 across the 55 interventional studies. Of the 47 that completed or were terminated, 18 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 55 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
74 studies in Pain by Pfizer: none open now, none under way, none of them phase 3. Of 72 finished, 34 (47%) have results posted.
Among the 74 studies in Pain by Pfizer, this one is the 42nd largest by enrollment of the 71 interventional ones that give a count, is one of 10 that started in 2006, is one of 20 in phase 2, and was the 7th registered.
Pfizer’s Pain studies by the year they started, since 2001.
3 of the studies testing pregabalin in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186751Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07208357Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07171320Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 55 studies testing pregabalin in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 74 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effectiveness of adjunctive treatment of pregabalin with [S,S]-Reboxetine against pregabalin monotherapy in patients with PHN
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: [S,S]-Reboxetine + Pregabalin
Drug: Pregabalin
Drug pages: Reboxetine · Pregabalin
\[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
The numerical pain intensity rating scale is used to assess pain and a change from baseline in pain score for week 10 will be calculated
Time frame: Week 10
The mean endpoint (week 10) sleep interference score change from baseline
Time frame: Week 10
Analysis of the Medical Outcomes Study Sleep Scale
Time frame: Week 10
Analysis of the Patient Global Impression of Change
Time frame: Week 10
Analysis of the Neuropathic Pain Symptom Inventory
Time frame: Week 10
Ran from Aug 2006 to primary completion in Oct 2007, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Reboxetine · Pregabalin